Роль ингибиторов EGFR 2-го поколения в терапии рака легкого в реалиях современной клинической практики

ИЗМАЙЛОВ, А.А.; НАСРЕТДИНОВ, А.Ф.; СУЛТАНБАЕВ, А.В.; САКАЕВА, Д.Д.; МЕНЬШИКОВ, К.В.; СУЛТАНБАЕВА, Н.И.; МУСИН, Ш.И.; Izmailov, A.A.; Nasretdinov, A.F.; Sultanbaev, A.V.; Sakaeva, D.D.; Menshikov, K.V.; Sultanbaeva, N.I.; Musin, Sh. I.

Modern third-generation tyrosine kinase inhibitors (TKIs) show amazing results in the treatment of EGFR-mutated lung tumors, overshadowing the earlier generation representatives. Does this mean that it is necessary to completely abandon other TKIs in fa-vor of osimertinib? In search of an answer to this question, the authors have analyzed works on the efficacy of the most interest-ing representative of TKIs, such as second-generation irreversible non-selective EGFR inhibitors. Afatinib from this group has been registered in the Russian Federation. The paper reveals possible niches for the use of afatinib, gives its comparative efficacy with other TKIs, assesses the possible mechanisms of its antitumor effect, and considers the problems that can be encountered when in-terpreting the results of studies. Afatinib as a representative of second-generation EGFR inhibitors shows extremely good results in the treatment of non-small cell lung cancer: it demonstrates effectiveness in first-line therapy, can bring benefits to patients after T790M-independent progression in first-and second-line TKI therapy for squamous cell lung cancer after progression during platinum-based therapy, and also has promising data from sequential afatinib — osimertinib treatment. © 2021, Media Sphera Publishing Group. All rights reserved.

Роль ингибиторов EGFR 2-го поколения в терапии рака легкого в реалиях современной клинической практики

The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice

Фасеты

Оппонент

Научный руководитель

Авторы

Ключевые слова

Год